Feb 22, 2019
In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCI) extended-release tablets CII (current Full ... Read more
Feb 20, 2019
Survey study sponsored by Purdue Pharma and published in the Journal of Pain Research examines factors that contribute ... Read more
Feb 4, 2019
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant ... Read more
Jan 28, 2019
Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and is eligible to ... Read more
Jan 22, 2019
Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult ... Read more
Jan 15, 2019
TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue ... Read more
Jan 7, 2019
Partners to research novel targets for reductions in pain STAMFORD, Conn., and BEDFORD, Mass., January 7, 2019 – ... Read more
Nov 6, 2018
STAMFORD, Conn., November 6, 2018 – Purdue Pharma L.P. today announced that the first patient has been enrolled in a ... Read more
Oct 22, 2018
Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near ... Read more
Oct 17, 2018
Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy ... Read more
for Healthcare Professionals 
for Patients & Caregivers 
Addressing the Crisis 
Partnering 